Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYHA1813 Oral Solution in Patients with Recurrent or Advanced Solid Tumor

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SYHA 1813 (Primary)
Indications Brain metastases; Colorectal cancer; Gastric cancer; Giant cell tumour of tendon sheath; Glioma; Lung cancer; Meningioma; Renal cancer; Solid tumours; Thyroid cancer
Focus Adverse reactions; Therapeutic Use

24 Oct 2023 Early findings (As of Apr. 12, 2023, n=11) from patients treated with SYHA1813 in the recurrent meningioma cohort, presented at the 48th European Society for Medical Oncology Congress.
08 Mar 2023 Results (n=14) assessing the safety, pharmacokinetics, and antitumor activity of escalating doses of SYHA1813 in patients with recurrent high-grade gliomas and colorectal cancer, published in the Investigational New Drugs.
15 Nov 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com